Takeda strengthens oncology pipeline with elritercept through licensing agreement with keros therapeutics

Osaka, japan & cambridge, mass.--(business wire)--takeda (tse:4502/nyse:tak) today announced that it has entered into an exclusive licensing agreement with keros therapeutics, inc. (nasdaq: kros) to further develop, manufacture and commercialize elritercept worldwide outside of mainland china, hong kong and macau. elritercept is a late-stage investigational activin inhibitor designed to treat anemia associated with certain hematologic cancers, including myelodysplastic syndromes (mds) and myelo.
TAK Ratings Summary
TAK Quant Ranking